Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate. Issue 3 (3rd March 2016)

• Record Type: Journal Article
• Authors: Akard, Luke; Kantarjian, Hagop M.; Nicolini, Franck E.; Wetzler, Meir; Lipton, Jeffrey H.; Baccarani, Michele; Jean Khoury, H.; Kurtin, Sandra; Li, Elizabeth; Munteanu, Mihaela; Cortes, Jorge
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 3(2016:Mar.)
• Page Start: 654
• Page End: 665
• Publication Date: 2016-03-03
• Subjects: Hematologic toxicity -- neutropenia -- omacetaxine mepesuccinate -- supportive care -- thrombocytopenia; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1071486
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Omacetaxine mepesuccinate (Synribo®) is an inhibitor of protein synthesis indicated for the treatment of patients with chronic- or accelerated-phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Myelosuppression is the most common and clinically significant toxicity experienced by patients treated with omacetaxine. Here, we further examine the patterns of hematologic toxicity observed in clinical trials and describe the approach to management as well as resolution of events. Omacetaxine-related myelosuppression typically occurs more frequently during induction cycles. In general, the myelosuppression observed with omacetaxine treatment is manageable and reversible, and long-term administration is feasible. Careful monitoring, dose delays and reduction in administration days, and appropriate supportive care are critical for successful management of hematologic toxicity. Concerns regarding myelosuppression, observed with many cancer treatments, should not prevent eligible patients from receiving omacetaxine, particularly CML patients with unsatisfactory responses to multiple lines of prior treatment.